Drug Profile
Research programme: anti-inflammatory therapeutics - Kaken Pharmaceuticals/Numab
Alternative Names: ND 026; ND-026 programmeLatest Information Update: 11 Sep 2020
Price :
$50
*
At a glance
- Originator Numab
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation